Research Papers:

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma

Kesang Li, Xiaorong Pan, Yanyu Bi, Wen Xu, Cheng Chen, Huiping Gao, Bizhi Shi, Hua Jiang, Shengli Yang, Liyan Jiang and Zonghai Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:2496-2507. https://doi.org/10.18632/oncotarget.6595

Metrics: PDF 2833 views  |   HTML 3940 views  |   ?  


Kesang Li1, Xiaorong Pan1, Yanyu Bi1, Wen Xu1, Cheng Chen1, Huiping Gao1, Bizhi Shi1, Hua Jiang1, Shengli Yang1, Liyan Jiang2, Zonghai Li1

1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

2Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Correspondence to:

Zonghai Li, e-mail: [email protected]

Keywords: lung squamous cell carcinoma, chimeric antigen receptor, glypican-3, CAR T cell

Received: August 12, 2015     Accepted: November 21, 2015     Published: December 14, 2015


There are unmet medical needs for patients with lung squamous cell carcinoma (LSCC). Therefore, in this study, we explored the antitumor potential of third-generation glypican 3 (GPC3)-redirected chimeric antigen receptor (CAR)-engineered T lymphocytes (CARgpc3 T cells) in tumor models of LSCC. First, we demonstrated by immunohistochemistry (IHC) that GPC3 was expressed in 66.3% of LSCC samples and in 3.3% of lung adenocarcinoma (LAD) samples but not in normal lung tissues. In the presence of GPC3-positive LSCC cells, CARgpc3 T cells were highly activated and increased in number. CARgpc3 T cells could specifically lyse GPC3-positive LSCC cells in vitro. In two established LSCC xenograft models, CARgpc3 T cells could almost completely eliminate the growth of GPC3-positive cells. Additionally, the CARgpc3 T cells were able to persist in vivo and efficiently infiltrate the cancerous tissues. Taken together, these findings indicate that CARgpc3 T cells might be a novel potential therapeutic agent for the treatment of patients with LSCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6595